Gold and silver prices edged higher as expectations for Federal Reserve rate hikes in October eased, providing support to bullion. However, gains were limited by elevated U.S. Treasury yields and a strong U.S. dollar. U.S. equities showed modest gains after volatile trading influenced by Treasury market swings. Key upcoming events include Friday's U.S. nonfarm payroll report, which could impact Fed rate expectations and precious metals prices. Geopolitical tensions around the Strait of Hormuz and oil prices also add uncertainty but currently support safe-haven demand for gold.
Gold price context shows mixed US stock performance on Pluang as of Oct 02, 2026 03:41 WIB. Out of 150 US stocks, 72 rose and 78 fell. Nike Inc (NKE) dropped 4.55% to USD 33.79 with a typical hold time of 155 days and 61% buy orders. IQIYI Inc (IQ) fell 3.94% to USD 0.99, held typically for 54 days, with 55% buy orders. Applied Materials (AMAT) rose 3.38% to USD 528.65, held for 66 days, with 86% sell orders.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
